Lido Advisors
ALXN

Lido Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Lido Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,846
Closed -$339K – 1045
2021
Q2 		$339K Buy
1,846
+70
+4% +$12K ﹤0.01% 672
2021
Q1 		$272K Buy
1,776
+137
+8% +$21.2K ﹤0.01% 696
2020
Q4 		$256K Buy
+1,639
New +$211K 0.01% 680
2020
Q1 		– Sell
-4,768
Closed -$516K – 702
2019
Q4 		$516K Sell
4,768
-43
-0.9% -$4.6K 0.02% 383
2019
Q3 		$471K Buy
4,811
+2,659
+124% +$300K 0.02% 345
2019
Q2 		$281K Buy
2,152
+22
+1% +$2.83K 0.02% 437
2019
Q1 		$287K Buy
+2,130
New +$265K 0.02% 403

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return